Browsing by Author "Boz C."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Economic impact of primary headaches in Turkey: A university hospital based study: Part II
    (2006) Karli N.; Zarifoǧlu M.; Ertaş M.; Saip S.; Öztürk V.; Biçakçi Ş.; Boz C.; Selçuki D.; Oǧuzhanoǧlu A.; Neyal M.; Siva A.; Irkeç C.; Kaleaǧasi H.; Kansu T.; Sarica Y.; Taşdemir N.; Uzuner N.
    This study was planned to investigate the economic impact of headache on Turkish headache sufferers attending a tertiary care outpatient headache clinic. A total of 937 headache patients were included in this study and questioned using a questionnaire for the profile of patients and headache, quality of life of patients and economic impact of headache. The median total direct cost was found to be 88.0 USD and the median total cost was 160.7 USD. The drug treatment cost was the highest item followed by the specialist outpatient care cost. The average lost and inefficient work/school days was 1.5 (0-45) and 8.4 (0-100) days for one year. It was shown that loss of productivity was higher for migraine without aura group when compared with the episodic and chronic tension-type headache groups. The results of this nationwide university hospital based study showed that headache, especially migraine, has considerable economic impact on patients. © Springer-Verlag Italia 2006.
  • No Thumbnail Available
    Item
    Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
    (Galenos Publishing House, 2024) Koç S.; Şen S.; Terzi Y.; Kızılay F.; Demir S.; Aksoy D.B.; Kurtuluş F.; Bilge N.; Idilman E.; Uzunköprü C.; Güngör S.; Çilingir V.; Ethemoğlu Ö.; Boz C.; Gümüş H.; Kılıç A.K.; Kısabay A.; Bir L.S.; Turan Ö.F.; Soysal A.; Köseoğlu M.; Uzuner G.T.; Bayındır H.; Kabay S.C.; Çam M.; Yayla V.; Tan H.; Özcan A.; Taşkapıoğlu Ö.; Korkmaz M.; Tamam Y.; İnanç Y.; Efendi H.; Kotan D.; Yetkin M.F.; Bilgiç A.B.; Saçmacı H.; Demirci S.; Çelik Y.; Poyraz T.; Terzi M.
    Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University’s Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG. © Author(s).